Literature DB >> 22004083

Symmetric division versus asymmetric division: a tale of two coactivators.

Michael Kahn1.   

Abstract

The decision for a stem cell to undergo a symmetric versus an asymmetric differentiation is probably the most critical cellular decision process in adults, as it probably underlies a large array of diseases, is associated with a decrease in tissue maintenance/homeostasis and the ability to repair properly, may mediate pathological processes such as cancer, fibrosis and neurodegeneration, and may be the underlying problem associated in general with aging. Interestingly and importantly, the decision to divide asymmetrically or symmetrically may be the major fundamental intrinsic difference between normal somatic stem and cancer stem cells. Based upon work done primarily in our laboratory over the past 10 years (both published and unpublished data), the article provides perspective on the critical importance of symmetric versus asymmetric divisions and the role of differential usage of the highly homologous coactivators Creb-binding protein (CBP) or p300 in the Wnt/catenin signaling cascade in stem cells and how they can be pharmacologically manipulated.

Entities:  

Mesh:

Year:  2011        PMID: 22004083     DOI: 10.4155/fmc.11.126

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  25 in total

Review 1.  Development of anticancer agents targeting the Wnt/β-catenin signaling.

Authors:  Xiangqian Zhang; Jijun Hao
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

Review 2.  Can we safely target the WNT pathway?

Authors:  Michael Kahn
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

Review 3.  Taking the road less traveled - the therapeutic potential of CBP/β-catenin antagonists.

Authors:  Michael Kahn
Journal:  Expert Opin Ther Targets       Date:  2021-10-27       Impact factor: 6.902

4.  The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.

Authors:  Michael D Arensman; Donatello Telesca; Anna R Lay; Kathleen M Kershaw; Nanping Wu; Timothy R Donahue; David W Dawson
Journal:  Mol Cancer Ther       Date:  2014-07-31       Impact factor: 6.261

5.  p300/β-Catenin Interactions Regulate Adult Progenitor Cell Differentiation Downstream of WNT5a/Protein Kinase C (PKC).

Authors:  Megan E Rieger; Beiyun Zhou; Nicola Solomon; Mitsuhiro Sunohara; Changgong Li; Cu Nguyen; Yixin Liu; Jie-hong Pan; Parviz Minoo; Edward D Crandall; Steven L Brody; Michael Kahn; Zea Borok
Journal:  J Biol Chem       Date:  2016-02-01       Impact factor: 5.157

6.  p300 Serine 89: A Critical Signaling Integrator and Its Effects on Intestinal Homeostasis and Repair.

Authors:  Keane K Y Lai; Xiaohui Hu; Keisuke Chosa; Cu Nguyen; David P Lin; Keith K Lai; Nobuo Kato; Yusuke Higuchi; Sarah K Highlander; Elizabeth Melendez; Yoshihiro Eriguchi; Patrick T Fueger; Andre J Ouellette; Nyam-Osor Chimge; Masaya Ono; Michael Kahn
Journal:  Cancers (Basel)       Date:  2021-03-14       Impact factor: 6.639

Review 7.  Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics.

Authors:  Roya Tabatabai; Yuliya Linhares; David Bolos; Monica Mita; Alain Mita
Journal:  Target Oncol       Date:  2017-10       Impact factor: 4.864

8.  Wnt3a/β-Catenin/CBP Activation in the Progression of Cervical Intraepithelial Neoplasia.

Authors:  Dingqing Feng; Jie Lin; Wenhui Wang; Keqin Yan; Haiyan Liang; Jing Liang; Huan Yu; Bin Ling
Journal:  Pathol Oncol Res       Date:  2021-03-31       Impact factor: 3.201

9.  Fibroblast growth factor receptor-mediated activation of AKT-β-catenin-CBP pathway regulates survival and proliferation of murine hepatoblasts and hepatic tumor initiating stem cells.

Authors:  Nirmala Mavila; David James; Sarah Utley; Nguyen Cu; Orly Coblens; Katrina Mak; C Bart Rountree; Michael Kahn; Kasper S Wang
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.

Authors:  E J Gang; Y-T Hsieh; J Pham; Y Zhao; C Nguyen; S Huantes; E Park; K Naing; L Klemm; S Swaminathan; E M Conway; L M Pelus; J Crispino; C G Mullighan; M McMillan; M Müschen; M Kahn; Y-M Kim
Journal:  Oncogene       Date:  2013-06-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.